Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Regulation of different inflammatory diseases by impacting the mevalonate pathway Zeiser R; Maas K; Youssef S; Durr C; Steinman L; Negrin RSImmunology 2009[May]; 127 (1): 18-25The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) interfere with the mevalonate pathway. While initially developed for their lipid-lowering properties, statins have been extensively investigated with respect to their impact on autoantigen and alloantigen driven immune responses. Mechanistically it was shown that statins modify immune responses on several levels, including effects on dendritic cells, endothelial cells, macrophages, B cells and T cells. Several lines of evidence suggest that statins act in a disease-specific manner and are not effective in each immune disorder. This review discusses possible modes of action of statins in modulating immunity towards autoantigens and alloantigens.|Animals[MESH]|Autoimmune Diseases/*drug therapy/immunology[MESH]|Autoimmunity/drug effects[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use[MESH]|Immunologic Factors/*pharmacology/therapeutic use[MESH]|Mevalonic Acid/*metabolism[MESH]|Signal Transduction/drug effects[MESH] |
